Asset Details
Do you wish to reserve the book?
Rus-GXF, a ruscogenin glycoside, binds to the ADP-binding domain of JAK1 to prevent inflammation and barrier damage in acute lung injury
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rus-GXF, a ruscogenin glycoside, binds to the ADP-binding domain of JAK1 to prevent inflammation and barrier damage in acute lung injury
Do you wish to request the book?
Rus-GXF, a ruscogenin glycoside, binds to the ADP-binding domain of JAK1 to prevent inflammation and barrier damage in acute lung injury
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rus-GXF, a ruscogenin glycoside, binds to the ADP-binding domain of JAK1 to prevent inflammation and barrier damage in acute lung injury
2026
Overview
Ruscogenin-1-O-[β-D-glucopyranosyl (1→2)][β-D-xylopyranosyl (1→3)] -β-D-fucopyranoside (Rus-GXF) is a ruscogenin glycoside of
(Decaisne) L. H. Bailey, yet its protective effects against acute lung injury-a condition characterized by exacerbated inflammation and barrier damage have not been fully elucidated.
In this study, the preventive and therapeutic effects of Rus-GXF on acute lung injury (ALI) were investigated using transcriptome RNA sequencing, network pharmacology, molecular docking, molecular dynamics simulation and other
and
experiments.
Rus-GXF suppressed inflammatory responses in two key cell types involved in lung injury. In immune cells (RAW264.7), it inhibited the production of pivotal pro-inflammatory mediators and their regulatory genes. Similarly, in pulmonary epithelial cells (BEAS-2B), it reduced the expression of inflammatory signals and concurrently enhanced markers of cellular tight junction proteins. In mice, Rus-GXF alleviated ALI severity, evidenced by decreased lung wet/dry ratio, bronchoalveolar lavage fluid protein content, pro-inflammatory cytokine levels, and histopathological scores. Integrated network pharmacology and transcriptomics indicated that Rus-GXF acts through multi-target mechanisms in ALI. Molecular docking and dynamics simulations revealed that Rus-GXF acts as an allosteric inhibitor of JAK1, thereby preventing its activation and subsequent STAT3 phosphorylation. The inhibitory effect of Rus-GXF on the JAK1/STAT3 signaling pathway was investigated by immunohistochemistry (IHC) and Western blot analysis (WB).
These results demonstrate that Rus-GXF suppresses the macrophage-derived cytokine storm, alleviates inflammation, and improves barrier function. It functions as a JAK1 inhibitor to regulate ALI progression via the JAK1/STAT3 signaling pathway.
